阿尔茨海默病脑脊液生物标志物在第三级神经病学实践中
Wentao Li1, Ronald C Petersen2, Alicia Algeciras-Schimnich3
1Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology, Kaiser Permanente South Sacramento, Sacramento, CA.
Mayo Clinic proceedings
|June 27, 2024
概括
在复杂的情况下,p-Tau181/Aβ42比率可以有效地识别阿尔茨海默病 (AD). 这一比率有助于区分AD与正常压力头症 (NPH),即使脑脊液动态发生变化.
科学领域:
- 神经学 神经学
- 生物化学 生物化学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于脑脊液 (CSF) 的生物标志物.
- 三级神经病学诊所经常看到各种病例,包括正常压力水头 (NPH),使生物标志物的解释复杂化.
- 脑脊髓动力学障碍可以影响生物标志物度.
研究的目的:
- 在混合临床群体中评估ADCSF生物标志物 (Aβ42,p-Tau181,总Tau) 的性能.
- 评估这些生物标志物的实用性,以区分AD和NPH.
- 调查CSF动态障碍对生物标志物水平的影响.
主要方法:
- 分析了534名接受AD CSF生物标志物测试的患者.
- 由神经病学家对CSF结果视而不见的回顾性临床诊断.
- 神经放射学家对脑部MRI进行评估,以发现CSF动态障碍.
- 统计分析包括千平方,ANCOVA和线性回归.
主要成果:
- 临床诊断与CSF生物标志物值有显著的相关性.
- 超过0.023的p-Tau181/Aβ42比率显示出与阿尔茨海默氏症痴呆症的最强相关性.
- 这一比率在区分阿尔茨海默氏症痴呆症与NPH (AUC=0.869) 中表现出很高的性能.
- 脑动力学障碍的成像标记与较低的Aβ42,p-Tau181和总-Tau相关.
结论:
- 异常的p-Tau181/Aβ42比率与异质人群中的阿尔茨海默氏症痴呆症密切相关.
- 这一比率可能表明非AD综合征中的并发性AD病理.
- 改变的CSF动态会影响生物标志物度,但该比率可以补偿.
- 孤立的低Aβ42可能表明NPH.
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110